

USA, Native American (1998-2012)

	Number of cases							Percentage				Incidence rates per million person-years							MV % 0-19	DCO % 0-19			
	Age group							0-14		0-19		Age-specific					Cumulative						
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	0-19			0-14	0-19	
I LEUKAEMIA	36	196	114	97	119	443	562	35.9	100.0	30.4	100.0	36.9	51.7	23.8	19.3	23.4	32.1	30.2	459	576	97.2	1.2	
a. Lymphoid	15	163	87	53	56	318	374	25.8	71.8	20.2	66.5	15.4	43.0	18.2	10.6	11.0	23.4	20.6	330	386	97.9	1.1	
b. Acute myeloid	9	24	17	34	40	84	124	6.8	19.0	6.7	22.1	9.2	6.3	3.6	6.8	7.9	5.8	6.3	86	126	99.2	0.8	
c. CMD	2	2	1	5	12	10	22	0.8	2.3	1.2	3.9	2.1	0.5	0.2	1.0	2.4	0.7	1.1	10	22	86.4	0.0	
d. MDS & other	9	4	5	3	5	21	26	1.7	4.7	1.4	4.6	9.2	1.1	1.0	0.6	1.0	1.6	1.4	22	27	96.2	0.0	
e. Unspecified	1	3	4	2	6	10	16	0.8	2.3	0.9	2.8	1.0	0.8	0.8	0.4	1.2	0.7	0.8	10	16	81.3	12.5	
II LYMPHOMA & RELATED	8	32	25	53	82	118	200	9.6	100.0	10.8	100.0	8.2	8.4	5.2	10.6	16.1	8.0	9.8	121	201	98.0	0.5	
a. Hodgkin	0	3	4	15	48	22	70	1.8	18.6	3.8	35.0	-	0.8	0.8	3.0	9.4	1.4	3.2	22	69	100.0	0.0	
b. Non-Hodgkin except BL	0	8	12	29	26	49	75	4.0	41.5	4.1	37.5	-	2.1	2.5	5.8	5.1	3.1	3.6	50	75	94.7	1.3	
c. Burkitt (BL)	0	4	4	7	6	15	21	1.2	12.7	1.1	10.5	-	1.1	0.8	1.4	1.2	1.0	1.0	15	21	100.0	0.0	
d. Lymphoreticular	7	17	5	2	1	31	32	2.5	26.3	1.7	16.0	7.2	4.5	1.0	0.4	0.2	2.4	1.9	32	33	100.0	0.0	
e. Unspecified	1	0	0	0	1	1	2	0.1	0.8	0.1	1.0	1.0	-	-	-	0.2	0.1	0.1	1	2	100.0	0.0	
III CNS NEOPLASMS †	15	73	91	87	118	266	384	21.6	100.0	20.8	100.0	15.4	19.3	19.0	17.3	23.2	18.3	19.4	274	390	77.3	0.8	
a. Ependymoma	4	13	6	4	8	27	35	2.2	10.2	1.9	9.1	4.1	3.4	1.3	0.8	1.6	2.0	1.9	28	36	97.1	2.9	
b. Astrocytoma	6	28	33	31	27	98	125	7.9	36.8	6.8	32.6	6.2	7.4	6.9	6.2	5.3	6.8	6.4	101	128	88.0	0.0	
c. CNS embryonal	4	16	22	8	12	50	62	4.1	18.8	3.4	16.1	4.1	4.2	4.6	1.6	2.4	3.6	3.3	52	64	98.4	1.6	
d. Other gliomas	0	10	16	14	11	40	51	3.2	15.0	2.8	13.3	-	2.6	3.3	2.8	2.2	2.7	2.6	41	52	45.1	0.0	
e. Other specified	1	3	12	27	52	43	95	3.5	16.2	5.1	24.7	1.0	0.8	2.5	5.4	10.2	2.7	4.4	44	95	62.1	0.0	
f. Unspecified CNS	0	3	2	3	8	8	16	0.6	3.0	0.9	4.2	-	0.8	0.4	0.6	1.6	0.6	0.8	8	16	62.5	6.3	
IV NEUROBLASTOMA	27	36	5	1	3	69	72	5.6	100.0	3.9	100.0	27.7	9.5	1.0	0.2	0.6	5.5	4.4	72	75	100.0	0.0	
a. (Ganglio)neuroblastoma	27	36	5	1	1	69	70	5.6	100.0	3.8	97.2	27.7	9.5	1.0	0.2	0.2	5.5	4.3	72	73	100.0	0.0	
b. Peripheral nervous	0	0	0	0	2	0	2	-	-	0.1	2.8	-	-	-	-	0.4	-	0.1	-	2	100.0	0.0	
V RETINOBLASTOMA	12	12	2	0	1	26	27	2.1	100.0	1.5	100.0	12.3	3.2	0.4	-	0.2	2.1	1.7	27	28	77.8	3.7	
VI RENAL TUMOURS	10	42	9	2	6	63	69	5.1	100.0	3.7	100.0	10.3	11.1	1.9	0.4	1.2	4.9	4.1	66	72	98.6	0.0	
a. Nephroblastoma	10	41	7	0	1	58	59	4.7	92.1	3.2	85.5	10.3	10.8	1.5	-	0.2	4.6	3.6	61	62	100.0	0.0	
b. Renal carcinoma	0	1	2	2	5	5	10	0.4	7.9	0.5	14.5	-	0.3	0.4	0.4	1.0	0.3	0.5	5	10	90.0	0.0	
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
VII HEPATIC TUMOURS	6	18	4	2	3	30	33	2.4	100.0	1.8	100.0	6.2	4.7	0.8	0.4	0.6	2.3	1.9	31	34	100.0	0.0	
a. Hepatoblastoma	6	17	3	0	0	26	26	2.1	86.7	1.4	78.8	6.2	4.5	0.6	-	-	2.1	1.6	27	27	100.0	0.0	
b. Hepatic carcinoma	0	1	1	2	3	4	7	0.3	13.3	0.4	21.2	-	0.3	0.2	0.4	0.6	0.3	0.3	4	7	100.0	0.0	
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
VIII BONE TUMOURS	0	3	19	40	43	62	105	5.0	100.0	5.7	100.0	-	0.8	4.0	8.0	8.5	3.8	4.9	63	105	96.2	1.9	
a. Osteosarcoma	0	0	11	24	27	35	62	2.8	56.5	3.4	59.0	-	-	2.3	4.8	5.3	2.1	2.8	35	62	98.4	0.0	
b. Chondrosarcoma	0	0	1	0	2	1	3	0.1	1.6	0.2	2.9	-	-	0.2	-	0.4	0.1	0.1	1	3	100.0	0.0	
c. Ewing & related	0	3	6	13	10	22	32	1.8	35.5	1.7	30.5	-	0.8	1.3	2.6	2.0	1.4	1.5	22	32	96.9	3.1	
d. Other specified	0	0	1	2	1	3	4	0.2	4.8	0.2	3.8	-	-	0.2	0.4	0.2	0.2	0.2	3	4	100.0	0.0	
e. Unspecified	0	0	0	1	3	1	4	0.1	1.6	0.2	3.8	-	-	-	0.2	0.6	0.1	0.2	1	4	50.0	25.0	
IX SOFT TISSUE SARCOMA	6	28	12	26	46	72	118	5.8	100.0	6.4	100.0	6.2	7.4	2.5	5.2	9.0	5.1	6.0	74	119	100.0	0.0	
a. Rhabdomyosarcoma	1	20	3	8	8	32	40	2.6	44.4	2.2	33.9	1.0	5.3	0.6	1.6	1.6	2.4	2.2	33	41	100.0	0.0	
b. Fibrosarcoma	4	0	2	1	2	7	9	0.6	9.7	0.5	7.6	4.1	-	0.4	0.2	0.4	0.5	0.5	7	9	100.0	0.0	
c. Kaposi sarcoma	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
d. Other specified	1	7	6	15	32	29	61	2.4	40.3	3.3	51.7	1.0	1.8	1.3	3.0	6.3	1.9	2.9	30	61	100.0	0.0	
e. Unspecified	0	1	1	2	4	4	8	0.3	5.6	0.4	6.8	-	0.3	0.2	0.4	0.8	0.3	0.4	4	8	100.0	0.0	
X GERM CELL TUMOURS	8	5	4	16	75	33	108	2.7	100.0	5.8	100.0	8.2	1.3	0.8	3.2	14.7	2.3	5.1	34	107	98.1	0.0	
a. CNS germ cell	2	1	1	8	3	12	15	1.0	36.4	0.8	13.9	2.1	0.3	0.2	1.6	0.6	0.8	0.7	12	15	93.3	0.0	
b. Other extragonadal	4	1	2	0	9	7	16	0.6	21.2	0.9	14.8	4.1	0.3	0.4	-	-	1.8	0.5	0.8	7	16	93.8	0.0
c. Gonadal germ cell	2	3	1	7	61	13	74	1.1	39.4	4.0	68.5	2.1	0.8	0.2	1.4	12.0	0.9	3.4	13	73	100.0	0.0	
d. Gonadal carcinoma	0	0	0	0	1	0	1	-	-	0.1	0.9	-	-	-	-	0.2	-	0.0	-	1	100.0	0.0	
e. Unspecified gonadal	0	0	0	1	1	1	2	0.1	3.0	0.1	1.9	-	-	-	0.2	0.2	0.1	0.1	1	2	100.0	0.0	
XI CARCINOMA & MELANOMA	1	4	10	29	115	44	159	3.6	100.0	8.6	100.0	1.0	1.1	2.1	5.8	22.6	2.8	7.2	45	158	100.0	0.0	
a. Adrenocortical	1	3	1	0	0	5	5	0.4	11.4	0.3	3.1	1.0	0.8	0.2	-	-	0.4	0.3	5	5	100.0	0.0	
b. Thyroid	0	1	2	13	47	16	63	1.3	36.4	3.4	39.6	-	0.3	0.4	2.6	9.2	1.0	2.8	16	62	100.0	0.0	
c. Nasopharyngeal	0	0	0	4	8	4	12	0.3	9.1	0.6	7.5	-	-	-	0.8	1.6	0.2	0.5	4	12	100.0	0.0	
d. Melanoma	0	0	4	5	10	9	19	0.7	20.5	1.0	11.9	-	-	0.8	1.0	2.0	0.6	0.9	9	19	100.0	0.0	
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
f. Other & unspecified	0	0	3	7	50	10	60	0.8	22.7	3.2	37.7	-	-	0.6	1.4	9.8	0.6	2.7	10	59	100.0	0.0	
XII OTHER & UNSPECIFIED	3	2	0	2	4	7	11	0.6	100.0	0.6	100.0	3.1	0.5	-	0.4	0.8	0.5	0.6	7	11	72.7	9.1	
a. Other specified	2	1	0	0	1	3	4	0.2	42.9	0.2	36.4	2.1	0.3	-	-	0.2	0.2	0.2	3	4	100.0	0.0	
b. Other unspecified	1	1	0	2	3	4	7	0.3	57.1	0.4	63.6	1.0	0.3	-	0.4	0.6	0.3	0.3	4	7	57.1	14.3	
TOTAL	132	451	295	355	615	1233	1848	100.0	100.0	100.0	100.0	135.4	118.9	61.7	70.7	120.9	87.8	95.2	1274	1878	93.3	0.8	

† includes 104 non-malignant

Please consult the quality indicators for the constituent registries

USA, Native American (1998-2012)

	Males										M/F ratio		Females											
	Number of cases in age groups										0-14	0-19	Number of cases in age groups										0-14	0-19
	0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19			0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19		
I LEUKAEMIA	19	113	63	48	66	243	309	35.0	32.8	1.2	1.2	17	83	51	49	53	200	253	29.2	27.5				
a. Lymphoid	7	94	50	32	39	183	222	26.5	23.9	1.4	1.5	8	69	37	21	17	135	152	20.2	17.2				
b. Acute myeloid	5	14	9	11	17	39	56	5.5	5.7	0.9	0.8	4	10	8	23	23	45	68	6.1	6.8				
c. CMD	0	2	0	3	5	5	10	0.7	0.9	1.0	0.8	2	0	1	2	7	5	12	0.7	1.2				
d. MDS & other	6	2	2	1	2	11	13	1.7	1.5	1.1	1.0	3	2	3	2	3	10	13	1.5	1.4				
e. Unspecified	1	1	2	1	3	5	8	0.7	0.8	1.0	1.0	0	2	2	1	3	5	8	0.7	0.8				
II LYMPHOMA & RELATED	4	23	15	42	40	84	124	11.1	12.1	2.5	1.6	4	9	10	11	42	34	76	4.8	7.5				
a. Hodgkin	0	2	2	11	21	15	36	1.8	3.2	2.1	1.1	0	1	2	4	27	7	34	0.9	3.2				
b. Non-Hodgkin except BL	0	7	7	23	15	37	52	4.7	4.9	3.1	2.3	0	1	5	6	11	12	23	1.6	2.2				
c. Burkitt (BL)	0	4	3	6	3	13	16	1.7	1.6	6.5	3.2	0	0	1	1	3	2	5	0.3	0.5				
d. Lymphoreticular	3	10	3	2	0	18	18	2.7	2.1	1.4	1.3	4	7	2	0	1	13	14	2.1	1.7				
e. Unspecified	1	0	0	0	1	1	2	0.2	0.2	-	-	0	0	0	0	0	0	0	-	-				
III CNS NEOPLASMS †	7	44	48	47	52	146	198	19.9	19.9	1.2	1.1	8	29	43	40	66	120	186	16.7	18.9				
a. Ependymoma	1	10	3	3	7	17	24	2.5	2.5	1.7	2.2	3	3	3	1	1	10	11	1.5	1.3				
b. Astrocytoma	5	14	20	15	13	54	67	7.4	6.9	1.2	1.2	1	14	13	16	14	44	58	6.1	6.0				
c. CNS embryonal	0	7	14	6	7	27	34	3.7	3.4	1.2	1.2	4	9	8	2	5	23	28	3.5	3.1				
d. Other gliomas	0	8	5	6	4	19	23	2.6	2.4	0.9	0.8	0	2	11	8	7	21	28	2.8	2.8				
e. Other specified	1	2	4	17	16	24	40	3.0	3.7	1.3	0.7	0	1	8	10	36	19	55	2.4	5.2				
f. Unspecified CNS	0	3	2	0	5	5	10	0.7	1.0	1.7	1.7	0	0	0	3	3	3	6	0.4	0.5				
IV NEUROBLASTOMA	8	15	3	0	2	26	28	4.1	3.3	0.6	0.6	19	21	2	1	1	43	44	7.0	5.5				
a. (Ganglioneuroblastoma	8	15	3	0	1	26	27	4.1	3.2	0.6	0.6	19	21	2	1	0	43	43	7.0	5.4				
b. Peripheral nervous	0	0	0	0	1	0	1	-	0.1	-	1.0	0	0	0	0	1	0	1	-	0.1				
V RETINOBLASTOMA	9	5	1	0	1	15	16	2.4	1.9	1.4	1.5	3	7	1	0	0	11	11	1.8	1.4				
VI RENAL TUMOURS	6	16	3	0	1	25	26	3.9	3.1	0.7	0.6	4	26	6	2	5	38	43	6.0	5.1				
a. Nephroblastoma	6	16	2	0	0	24	24	3.8	2.9	0.7	0.7	4	25	5	0	1	34	35	5.5	4.3				
b. Renal carcinoma	0	0	1	0	1	1	2	0.1	0.2	0.3	0.3	0	1	1	2	4	4	8	0.5	0.8				
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-				
VII HEPATIC TUMOURS	3	13	2	2	3	20	23	3.1	2.6	2.0	2.3	3	5	2	0	0	10	10	1.6	1.2				
a. Hepatoblastoma	3	13	1	0	0	17	17	2.7	2.1	1.9	1.9	3	4	2	0	0	9	9	1.4	1.1				
b. Hepatic carcinoma	0	0	1	2	3	3	6	0.4	0.5	3.0	6.0	0	1	0	0	0	1	1	0.2	0.1				
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-				
VIII BONE TUMOURS	0	3	13	22	19	38	57	4.7	5.3	1.6	1.2	0	0	6	18	24	24	48	2.9	4.5				
a. Osteosarcoma	0	0	8	12	13	20	33	2.4	3.0	1.3	1.1	0	0	3	12	14	15	29	1.8	2.7				
b. Chondrosarcoma	0	0	1	0	1	1	2	0.1	0.2	-	2.0	0	0	0	0	1	0	1	-	0.1				
c. Ewing & related	0	3	3	9	2	15	17	1.9	1.7	2.1	1.1	0	0	3	4	8	7	15	0.9	1.4				
d. Other specified	0	0	1	1	0	2	2	0.2	0.2	2.0	1.0	0	0	0	1	1	1	2	0.1	0.2				
e. Unspecified	0	0	0	0	3	0	3	-	0.3	0.0	3.0	0	0	0	1	0	1	1	0.1	0.1				
IX SOFT TISSUE SARCOMA	4	16	5	12	28	37	65	5.2	6.5	1.1	1.2	2	12	7	14	18	35	53	4.9	5.4				
a. Rhabdomyosarcoma	1	11	1	5	5	18	23	2.6	2.5	1.3	1.4	0	9	2	3	3	14	17	2.1	1.9				
b. Fibrosarcoma	3	0	0	1	1	4	5	0.6	0.5	1.3	1.3	1	0	2	0	1	3	4	0.4	0.4				
c. Kaposi sarcoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-				
d. Other specified	0	4	4	5	19	13	32	1.7	3.0	0.8	1.1	1	3	2	10	13	16	29	2.1	2.8				
e. Unspecified	0	1	0	1	3	2	5	0.3	0.5	1.0	1.7	0	0	1	1	1	2	3	0.3	0.3				
X GERM CELL TUMOURS	2	3	2	10	56	17	73	2.2	6.5	1.1	2.1	6	2	2	6	19	16	35	2.3	3.5				
a. CNS germ cell	1	0	1	6	3	8	11	1.0	1.0	2.0	2.8	1	1	0	2	0	4	4	0.6	0.4				
b. Other extragonadal	0	0	1	0	4	1	5	0.1	0.4	0.2	0.5	4	1	1	0	5	6	11	1.0	1.2				
c. Gonadal germ cell	1	3	0	4	49	8	57	1.1	5.1	1.6	3.4	1	0	1	3	12	5	17	0.7	1.6				
d. Gonadal carcinoma	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.1				
e. Unspecified gonadal	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	0	1	1	1	2	0.1	0.2				
XI CARCINOMA & MELANOMA	1	1	5	14	34	21	55	2.6	4.9	0.9	0.5	0	3	5	15	81	23	104	2.9	9.6				
a. Adrenocortical	1	0	0	0	0	1	1	0.2	0.1	0.3	0.3	0	3	1	0	0	4	4	0.6	0.5				
b. Thyroid	0	1	1	7	8	9	17	1.1	1.5	1.3	0.4	0	0	1	6	39	7	46	0.8	4.2				
c. Nasopharyngeal	0	0	0	2	6	2	8	0.2	0.7	1.0	2.0	0	0	0	2	2	2	4	0.2	0.4				
d. Melanoma	0	0	1	1	3	2	5	0.2	0.4	0.3	0.4	0	0	3	4	7	7	14	0.9	1.3				
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-				
f. Other & unspecified	0	0	3	4	17	7	24	0.9	2.1	2.3	0.7	0	0	0	3	33	3	36	0.4	3.3				
XII OTHER & UNSPECIFIED	1	0	0	2	1	3	4	0.4	0.4	0.8	0.6	2	2	0	0	3	4	7	0.7	0.8				
a. Other specified	1	0	0	0	0	1	1	0.2	0.1	0.5	0.3	1	1	0	0	1	2	3	0.3	0.3				
b. Other unspecified	0	0	0	2	1	2	3	0.2	0.3	1.0	0.8	1	1	0	0	2	2	4	0.3	0.4				
TOTAL	64	252	160	199	303	675	978	94.6	99.4	1.2	1.1	68	199	135	156	312	558	870	80.7	91.0				

† includes 48 non-malignant in males and 56 non-malignant in females

Please consult the quality indicators for the constituent registries

USA, Native American (1998-2012)

	Age group	Males	Females
Person-years	0	493 405	481 178
	1-4	1 924 249	1 867 388
	5-9	2 426 806	2 355 697
	10-14	2 537 735	2 481 822
	15-19	2 617 240	2 470 856
Total	0-14	7 382 195	7 186 085
	0-19	9 999 435	9 656 941
Average annual population	0-14	492 146	479 072
	0-19	666 629	643 796

Please consult the quality indicators for the constituent registries

USA, Native American (1998-2012)

Registry	Period	Cases	%	Person-years	%
Alabama	1998-2012	5	0.3	138 295	0.7
Alaska	1998-2012	154	8.3	700 022	3.6
Arizona	1998-2012	249	13.5	1 941 195	9.9
Arkansas	1998-2012	8	0.4	120 551	0.6
California	1998-2012	103	5.6	3 168 323	16.1
Colorado	1998-2012	23	1.2	388 276	2.0
Connecticut	1998-2012	3	0.2	83 934	0.4
Delaware	1998-2012	0	0.0	23 301	0.1
District of Columbia	1998-2012	2	0.1	11 019	0.1
Florida	1998-2012	18	1.0	386 774	2.0
Georgia	1998-2012	9	0.5	197 045	1.0
Hawaii	1998-2012	4	0.2	21 507	0.1
Idaho	1998-2012	15	0.8	144 328	0.7
Illinois	1998-2012	11	0.6	340 728	1.7
Indiana	1998-2012	1	0.1	116 915	0.6
Iowa	1998-2012	8	0.4	77 274	0.4
Kansas	1998-2012	7	0.4	196 377	1.0
Kentucky	1998-2012	2	0.1	45 098	0.2
Louisiana	1998-2012	3	0.2	162 310	0.8
Maine	1998-2012	5	0.3	47 682	0.2
Maryland	1998-2012	8	0.4	128 546	0.7
Massachusetts	1998-2012	10	0.5	142 092	0.7
Michigan	1998-2012	35	1.9	425 478	2.2
Minnesota	1998-2012	58	3.1	432 330	2.2
Mississippi	2002-2012	10	0.5	64 660	0.3
Missouri	1998-2012	5	0.3	165 987	0.8
Montana	1998-2012	70	3.8	405 895	2.1
Nebraska	1998-2012	13	0.7	140 811	0.7
Nevada	1998-2012	15	0.8	213 479	1.1
New Hampshire	1998-2012	1	0.1	19 719	0.1
New Jersey	1998-2012	6	0.3	208 976	1.1
New Mexico	1998-2012	144	7.8	1 169 182	5.9
New York State	1998-2012	24	1.3	838 487	4.3
North Carolina	1998-2012	53	2.9	674 088	3.4
North Dakota	1998-2012	42	2.3	234 062	1.2
Ohio	1998-2012	7	0.4	160 087	0.8
Oklahoma	1998-2012	345	18.7	2 050 180	10.4
Oregon	1998-2012	41	2.2	370 293	1.9
Pennsylvania	1998-2012	9	0.5	179 635	0.9
Rhode Island	1998-2012	3	0.2	49 849	0.3
South Carolina	1998-2012	2	0.1	98 597	0.5
South Dakota	2001-2012	50	2.7	401 309	2.0
Tennessee	1999-2012	7	0.4	94 691	0.5
Texas	1998-2012	60	3.2	1 083 009	5.5
Utah	1998-2012	21	1.1	248 719	1.3
Vermont	1998-2012	0	0.0	13 278	0.1
Virginia	1998-2012	4	0.2	159 528	0.8
Washington State	1998-2012	106	5.7	725 331	3.7
West Virginia	1998-2012	0	0.0	12 927	0.1
Wisconsin	1998-2012	55	3.0	348 937	1.8
Wyoming	1998-2012	14	0.8	85 260	0.4
USA	1998-2012	1848	100.0	19 656 376	100.0

America, North

Alaska, Native American
(1998-2012)Arizona, Native American
(1998-2012)

	Alaska, Native American (1998-2012)			Arizona, Native American (1998-2012)								
	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR						
I LEUKAEMIA	38	1.2	77.7	45	1.3	69.2	62	0.9	44.2	85	1.2	44.7
a. Lymphoid	20	1.0	43.0	22	1.2	35.9	46	1.4	33.2	61	1.5	32.6
b. Acute myeloid	12	2.0	22.9	15	1.5	21.6	11	0.2	7.4	17	0.5	8.5
c. CMD	1	.	1.6	1	.	1.2	2	0.0	1.4	4	1.0	2.0
d. MDS & other	4	1.0	8.3	5	0.7	7.7	1	0.0	0.8	1	0.0	0.6
e. Unspecified	1	0.0	1.9	2	1.0	2.8	2	1.0	1.4	2	1.0	1.1
II LYMPHOMA & RELATED	15	2.8	30.3	23	1.9	33.9	17	1.1	11.5	20	1.2	10.3
a. Hodgkin	2	.	3.8	4	3.0	5.5	2	1.0	1.3	3	2.0	1.5
b. Non-Hodgkin except BL	5	4.0	9.2	10	1.5	13.6	6	1.0	3.7	7	1.3	3.4
c. Burkitt (BL)	1	.	2.2	2	.	3.0	2	1.0	1.3	3	0.5	1.5
d. Lymphoreticular	6	1.0	12.8	6	1.0	9.9	7	1.3	5.2	7	1.3	4.1
e. Unspecified	1	.	2.2	1	.	1.7	0	.	.	0	.	.
III CNS NEOPLASMS †	17	1.1	32.5	35	0.6	48.4	46	1.9	31.3	58	1.3	29.7
a. Ependymoma	2	.	4.5	2	.	3.5	3	.	2.4	3	.	1.8
b. Astrocytoma	7	0.8	13.7	10	0.7	14.5	15	2.0	10.2	16	1.7	8.4
c. CNS embryonal	2	1.0	4.2	2	1.0	3.2	11	1.8	7.4	13	1.6	6.7
d. Other gliomas	2	0.0	3.8	3	0.0	4.2	8	1.0	5.6	9	0.8	4.8
e. Other specified	4	3.0	6.3	17	0.4	21.7	9	2.0	5.7	16	0.8	7.6
f. Unspecified CNS	0	.	.	1	.	1.3	0	.	.	1	.	0.5
IV NEUROBLASTOMA	4	1.0	9.0	4	1.0	7.0	2	1.0	1.6	2	1.0	1.2
a. (Ganglio)neuroblastoma	4	1.0	9.0	4	1.0	7.0	2	1.0	1.6	2	1.0	1.2
b. Peripheral nervous	0	.	.	0	.	.	0	.	.	0	.	.
V RETINOBLASTOMA	2	.	4.2	2	.	3.2	1	.	0.8	1	.	0.6
VI RENAL TUMOURS	3	0.5	6.7	3	0.5	5.2	6	1.0	4.7	6	1.0	3.7
a. Nephroblastoma	3	0.5	6.7	3	0.5	5.2	6	1.0	4.7	6	1.0	3.7
b. Renal carcinoma	0	.	.	0	.	.	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.
VII HEPATIC TUMOURS	4	3.0	8.7	5	4.0	8.0	6	1.0	4.4	6	1.0	3.4
a. Hepatoblastoma	4	3.0	8.7	4	3.0	6.7	5	0.7	3.9	5	0.7	3.0
b. Hepatic carcinoma	0	.	.	1	.	1.3	1	.	0.6	1	.	0.5
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.
VIII BONE TUMOURS	6	.	10.8	6	.	8.4	7	2.5	4.3	13	1.6	6.1
a. Osteosarcoma	2	.	3.1	2	.	2.4	4	3.0	2.6	8	1.7	3.8
b. Chondrosarcoma	0	.	.	0	.	.	0	.	.	0	.	.
c. Ewing & related	3	.	5.7	3	.	4.4	2	.	1.2	3	2.0	1.4
d. Other specified	1	.	1.9	1	.	1.5	1	0.0	0.6	1	0.0	0.5
e. Unspecified	0	.	.	0	.	.	0	.	.	1	.	0.5
IX SOFT TISSUE SARCOMA	4	1.0	8.7	11	1.2	15.8	11	1.2	7.5	17	1.1	8.5
a. Rhabdomyosarcoma	1	0.0	2.2	4	1.0	5.6	5	4.0	3.5	6	2.0	3.2
b. Fibrosarcoma	2	1.0	4.5	2	1.0	3.5	0	.	.	1	0.0	0.5
c. Kaposi sarcoma	0	.	.	0	.	.	0	.	.	0	.	.
d. Other specified	1	.	1.9	3	2.0	4.1	5	0.3	3.2	9	0.8	4.3
e. Unspecified	0	.	.	2	1.0	2.6	1	.	0.8	1	.	0.6
X GERM CELL TUMOURS	1	.	2.2	3	0.5	4.3	5	0.7	3.7	22	3.4	10.7
a. CNS germ cell	0	.	.	0	.	.	2	1.0	1.6	2	1.0	1.2
b. Other extragonadal	0	.	.	1	0.0	1.3	0	.	.	1	.	0.5
c. Gonadal germ cell	1	.	2.2	2	1.0	3.0	3	0.5	2.2	18	5.0	8.5
d. Gonadal carcinoma	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	0	.	.	0	.	.	1	0.0	0.5
XI CARCINOMA & MELANOMA	2	.	3.5	17	0.3	22.1	4	0.3	2.7	16	0.8	7.5
a. Adrenocortical	0	.	.	0	.	.	1	0.0	0.8	1	0.0	0.6
b. Thyroid	2	.	3.5	9	0.8	11.7	1	.	0.6	4	0.3	1.8
c. Nasopharyngeal	0	.	.	1	0.0	1.3	0	.	.	2	.	0.9
d. Melanoma	0	.	.	0	.	.	2	0.0	1.3	3	0.5	1.5
e. Skin carcinoma	0	.	.	0	.	.	0	.	.	0	.	.
f. Other & unspecified	0	.	.	7	0.0	9.0	0	.	.	6	1.0	2.7
XII OTHER & UNSPECIFIED	0	.	.	0	.	.	1	0.0	0.8	3	0.5	1.5
a. Other specified	0	.	.	0	.	.	0	.	.	1	0.0	0.5
b. Other unspecified	0	.	.	0	.	.	1	0.0	0.8	2	1.0	1.1
TOTAL	96	1.7	194.2	154	1.1	225.5	168	1.2	117.5	249	1.3	128.0

† includes 18 non-malignant in Alaska 14 non-malignant in Arizona

Please consult the quality indicators for the constituent registries